Retrospective Study
Copyright ©The Author(s) 2024.
World J Gastroenterol. Jul 14, 2024; 30(26): 3221-3228
Published online Jul 14, 2024. doi: 10.3748/wjg.v30.i26.3221
Table 2 Impact of glucagon-like peptide-1 receptor agonist on colonoscopy preparation
Ref.
Selected population
Type of study
Patients (n)
Endpoint
Significant results
Yao et al[26]Patients on GLP-1 RAs (cases) and patients not taking GLP-1 RAs (controls)Retrospective cohort study446Comparing bowel prep quality using the BBPS between diabetic patients taking GLP-1 RAs (case group) and diabetic patients not on GLP-1 As (control group)BBPS score of < 5 was 15.5% in the case group vs 6.6 in the control group. 18.9% of the case group needed repeat colonoscopy as compared to 11.1% in the control group
Tong et al[27]Patients on liraglutide vs patients on sitagliptin vs patients not on GLP-1 RAsProspective observational study360Assess the incidence of inadequate bowel cleaning using the BBPS, in patients taking GLP-1 RAs vs DPP-4i vs patients not taking GLP-1 RANo statistical significance in the incidence of inadequate bowel cleaning was found between the liraglutide group, the sitagliptin group, and the control group P = 0.927. Patients with Type 2 Diabetes and peripheral neuropathy taking GLP-1 RA did have a significant increase in inadequate bowel cleaning when compared to the sitagliptin group (61.3% vs 32.1%, P = 0.022) and control group (61.3% vs 32.8%, P = 0.025)
Sharma et al[28]Patients aged 45-75 who had an outpatient elective colonoscopy between 2012 and 2015, took one of the following drugs–Byetta, Victoza, or BydureonRetrospective medical record analysis255Comparing bowel prep quality using high-volume polyethylene glycol electrolyte lavage solution among two groups, one taking a GLP-1 RA and other group not taking a GLP-1 RAThe percentage of satisfactory bowel preparations in the group taking a GLP-1 RA was 92.06% and 92.25% in the group not taking a GLP-1 RA